Business Daily Media

Business Marketing

.

Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies

  • Written by ACN Newswire - Press Releases

Eisai: Gilead Sciences Submits New Drug Application in Japan for Filgotinib for the Treatment of Ulcerative Colitis with an Inadequate Response to Conventional Therapies

TOKYO, Apr 23, 2021 - (JCN Newswire) - Gilead Sciences K.K. and Eisai Co., Ltd. today announced that Gilead submitted an application to Japan's Pharmaceuticals and Medical Devices Agency (PMDA) for approval of filgotinib for an additional indication to treat patients with moderately to severely active ulcerative colitis. Filgotinib is a new oral

Read more //?#

Popular

Airwallex and McLaren Racing pen multi-year partnership

Airwallex, a leading global payments and financial platform for modern businesses, today announced a multi-year partnership with the McLaren Formula 1 team, one of the sport’s most iconic brands. As an Official Partner, Airwal...

Building a trusted partnership with your Accountant in 2021

After a year of bushfires, floods, droughts, a global pandemic and resulting border closures, any business still standing deserves more than a medal. As this tumultuous time has presented ever-evolving challenges when it com...

Advanced Topics in IT

Information technology plays a key role in evolving the world. Individuals depend on innovative technology solutions to live their lives conveniently and perform daily activities without stress. Business leaders can also access ...